C-reactive Protein Is a Strong Predictor of Mortality in Hemodialysis Patients by Rački, Sanjin et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=irnf20
Renal Failure
ISSN: 0886-022X (Print) 1525-6049 (Online) Journal homepage: https://www.tandfonline.com/loi/irnf20
C-reactive Protein Is a Strong Predictor of Mortality
in Hemodialysis Patients
Sanjin Rački, Luka Zaputović, Žarko Mavrić, Božidar Vujičić & Štefica Dvornik
To cite this article: Sanjin Rački, Luka Zaputović, Žarko Mavrić, Božidar Vujičić & Štefica Dvornik
(2006) C-reactive Protein Is a Strong Predictor of Mortality in Hemodialysis Patients, Renal Failure,
28:5, 427-433, DOI: 10.1080/08860220600683581
To link to this article:  https://doi.org/10.1080/08860220600683581
Published online: 07 Jul 2009.
Submit your article to this journal 
Article views: 138
Citing articles: 24 View citing articles 
Renal Failure, 28:427–433, 2006 
Copyright © Informa Healthcare
ISSN: 0886-022X print / 1525-6049 online
DOI: 10.1080/08860220600683581
427
LRNFCLINICAL STUDY
C-reactive Protein Is a Strong Predictor of Mortality in Hemodialysis Patients
C-reactive Protein: A Predictor of MortalitySanjin Ra0ki, M.D.
Department of Nephrology and Dialysis, Rijeka University Hospital,  Rijeka, Croatia
Luka Zaputovic, M.D., Ph.D., and Zarko Mavric, M.D., Ph.D.
Department of Cardiology, Rijeka University Hospital, Rijeka, Croatia
Bozidar Vuji0ic, M.D.
Istrian Health Centres,  Health Centre Umag, Umag, Croatia
3tefica Dvornik, Ph.D.
Department of Laboratory Diagnostic,  Rijeka University Hospital, Rijeka, Croatia
Background. To establish the baseline cutoff value of C-
reactive protein (CRP) that would predict increased overall and
cardiovascular mortality in patients with end-stage renal disease
(ESRD). Methods. A cohort of 270 prevalent hemodialysis
patients treated at Rijeka University Hospital was eligible for the
study. Monthly CRP measurements were performed for three
consecutive months. Only the patients with CRP values varying
<20% were included (n=256). During the follow-up, 24 patients
were transplanted and therefore excluded from the analysis. The
CRP cutoff point of 6.2 mg/L was established by Receiver Oper-
ating Characteristic curve. The patients were divided into four
groups according to their CRP values. Group 1 included 80
(34.5%) patients with CRP <3.0 mg/L, group 2 included 23
(9.9%) patients with CRP 3.0–6.1 mg/L, group 3 consisted of 18
(7.7%) patients with CRP 6.2–10.0 mg/L, and group 4 included
111 (47.9%) patients with CRP >10.0 mg/L. The survival was
evaluated by Kaplan-Meier curve. Results. During the two-
year follow-up, 59 patients died. The major cause of death was
cardiovascular disease (64%). Significantly higher overall and
cardiovascular mortality was observed in group 3 when com-
pared with groups 1 and 2 (χ2=11.97; P < 0.001) and in group 4
when compared with groups 1 and 2 (χ2=14.40; P<0.001). Com-
pared with survivors, non-survivors had a higher median CRP
value (19.0 [1.5–99.7] mg/L vs. 2.3 [0.1–49.1] mg/L, respec-
tively; P<0.001). Conclusion. Serum concentration of CRP
above 6.2 mg/L is a strong predictor of overall and cardiovascu-
lar mortality in patients with ESRD.
Keywords chronic inflammation, C-reactive protein,
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INTRODUCTION
Cardiovascular disease (CVD) remains the major cause
of morbidity and mortality in patients with end-stage renal
disease (ESRD).[1] However, its unacceptably high inci-
dence in these patients cannot be fully explained by tradi-
tional risk factors, such as hypertension or dyslipidemia;[2]
other risk factors related to uremic milieu also play a role.[3]
Recent improvements in dialysis technology have not
decreased the mortality of maintenance dialysis patients,
which remains very high, even higher than that of patients
with malignant diseases.[4] Large multicentric clinical trials,
such as ADEMEX and HEMO studies, have failed to show
that the increased dialysis dose and use of high-flux dialysis
improve the survival of dialysis patients.[5,6]
Thus, the focus of research here has shifted on novel
cardiovascular risk factors in these patients. One of them
is chronic inflammation, considered a putative “secret
killer” and suspected to promote atherosclerosis.[7] The
role of inflammation in the atherosclerotic disease pro-
cess has become well-recognized over the past
decade.[8,9] The hemodialysis procedure itself contributes
to the inflammatory response. The possible contributing
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factors are the presence of catheter, graft, and fistula
infections, contamination of dialysis fluid, back-filtration
and back-diffusion of contaminated dialysate, and the
use of bio-incompatible membranes. The inflammatory
response strongly promotes the production of acute phase
proteins and proinflammatory cytokines. When com-
bined with malnutrition, which is more common in
patients with chronic inflammation, it predicts poor out-
come. Thus, malnutrition, inflammation, and atheroscle-
rosis (MIA) syndrome is the major risk factor for
premature death in patients with ESRD.[10]
Proinflammatory risk factors that can be measured
include oxidized low-density lipoproteins; proinflammatory
cytokines (i.e., interleukin [IL]-1 and tumour necrosis factor
[TNF]-α); adhesion molecules (i.e., intercellular adhesion
molecule-1 and selectins); inflammatory stimuli with
hepatic effects (i.e., IL-6); or the products of the hepatic
stimulation, such as serum amyloid A, C-reactive protein
(CRP), and many other acute-phase reactants. Finally, other
indicators of cellular response to inflammation, such as
increased white blood cell (WBC) count, are also possible
to evaluate.[11] Many of these inflammatory biomarkers,
such as CRP, IL-6, or WBC count, are robust predictors of
the outcome in patients with ESRD.[12]
Impaired immune response coupled with persistent
immune stimulation maintains low-grade systemic
inflammation and altered cytokine balance, which char-
acterize the uremic state and may translate into
increased CVD risk. The roles of cytokines are quite
different. Whereas the IL-10 has antiinflammatory
effects, the main proinflammatory cytokines, IL-6 and
TNF-α, have proatherogenic properties. The fact that
IL-6 promotes the production of CRP may be the reason
why IL-6 has been reported to be a proatherogenic and
its plasma concentration correlates with poor outcome
in patients with ESRD.[13] Although these cytokines,
acute phase reactants, and cellular responses to inflam-
matory stimuli might be predictive of the clinical
course of the disease, the laboratory tests to assess
inflammation are limited to those useful in clinical set-
tings, depending on commercially available assays that
can be standardized and adequate precision. Therefore,
it seems most reasonable to limit current assays of
inflammatory markers to high-sensitivity (hs) CRP.[11]
CRP baseline concentration correlates well with mortal-
ity in patients with ESRD and is independent of serum
albumin and other possible confounding factors.[14,15]
However, the CRP cutoff value that may indicate high
overall and cardiovascular mortality risk in these
patients has not yet been defined.[14,16] The aim of this
study was to determine the possible baseline cutoff
value of CRP as a predictor for increased mortality in
patients with ESRD.
PATIENTS AND METHODS
Patients and Study Design
A cohort of 270 prevalent hemodialysis patients
treated at Rijeka University Hospital, Croatia, between
December 2002 and November 2005 were found eligible
for the study. All patients were on chronic hemodialysis
for a minimum of three months and clinically stable with-
out any overt active inflammatory state, infection, or
infectious disease. None of them had a fever or was hospi-
talized within 30 days before the study. Patients with
autoimmune disease or malignancy and those taking
immunosuppressive therapy were excluded. Basic nutri-
tional and inflammatory markers were determined on a
monthly basis for three consecutive months. Monthly CRP
measurements for three consecutive months were per-
formed in all patients. Only the patients with CRP values
varying <20% were included in the study (see Figure 1).
The final sample consisted of 256 patients aged between
22 and 86 years.
Data were collected on demographic characteristics,
vascular access, underlying renal diseases, and the base-
line clinical status of the patients (see Table 1). Dialysis
Figure 1. Flow of the patients through the study.
256 with three 
consecutive CRP 
measurements included 
14 excluded due to CRP 
fluctuations 20% on 
three baseline
measurements 
72 survived 19 survived 12 survived 70 survived
Group 1 
CRP <3 
mg/L (n=89) 
Group 2 
CRP 3-6.1 
mg/L (n=25) 
Group 3 
CRP 6.2-10 
mg/L (n=20) 
Group 4 
CRP >10 mg/L 
(n=122) 
270 eligible patients
80 patients 
analysed 
23 patients 
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Transplanted 
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was performed for 12 hours, three times a week, by using
a steam-sterilized, low-flux polysulfone dialyser mem-
brane (Fresenius Polysulfone®, Fresenius Medical Care,
Bad Homburg, Germany) with 1.4 m2 and 1.8 m2 surface
area, and the bicarbonate-based dialysate at a delivered
bicarbonate concentration of 33 mEq/L. The blood flow
rate was maintained at 300–400 mL/min and the dialysate
flow rate at 500 mL/min. Concomitant medications, when
indicated, included antihypertensive medications (except
angiotensin-converting enzyme inhibitors), iron gluconate,
calcium-based phosphate binders, aspirin, active oral vita-
min D supplementation, and human recombinant erythro-
poietin therapy to maintain the hemoglobin concentration
above 110 g/L.
Chronic inflammation was defined as CRP >6.2 mg/L
on the basis of the receiver operating characteristics (ROC)
curve, which showed a threshold value of CRP > 6.2 mg/L
as predictive of death (see Figure 2). Using this CRP value
as a cutoff point, the patients were divided into four groups
according to the mean value of three consecutive CRP mea-
surements during the screening period. Group 1 included
patients with a normal CRP value range, according to the
laboratory standard (CRP <3.0 mg/L). Group 2 included
patients with increased CRP values but below the cutoff
point (CRP 3.0–6.1 mg/L). Group 3 consisted of patients
with CRP values above the cutoff point but below the com-
mon limit value in patients with ESRD (CRP 6.2–10.0 mg/
L), whereas group 4 included patients with CRP values
above that common limit (CRP >10.0 mg/L).[15–17]
Laboratory Testing
Blood samples (10 mL) for laboratory testing were
drawn from the venous part of a vascular access at the
beginning of the hemodialysis session, centrifuged within
two hours, and stored on ice (4°C).
The CRP values were determined by turbidimetric
immunoassay method on Olympus AU 400 autoanalyzer
(Olympus, Hamburg, Germany) using Olympus Diagnos-
tics reagents, according to the hsCRP application protocol
for Olympus instruments.[18] The detection interval for
CRP is 0.08–160.0 mg/L, and the reference interval of
serum CRP value is <1 mg/L.[19]
The baseline serum albumin was measured by the
bromcresol green method[20] on Olympus AU 400 autoan-
alyzer using Olympus Diagnostics reagents, according to
the application protocol for Olympus instruments.[18] The
detection interval for serum albumin is 15–60 g/L, and the
normal range is 35–52 g/L.[21]
Dialysis adequacy (Kt/V) was analyzed at baseline by
the Daugirdas equation.[22]
Table 1 
Characteristics of 256 chronic hemodialysis patients 
enrolled in the study
Characteristic Number of patients (%)
Age (mean±SD, years) 62 ± 13
Sex
Men 116 (45.3)
Women 140 (54.7)
Time on hemodialysis 
(mean±SD, months)
52 ± 38
CRP* (median, range, mg/L) 4.4 (0.1–99.7)
Serum albumin (mean±SD, g/L) 37 ± 4
Kt/V urea (mean±SD) 1.3 ± 0.3
Vascular access type
Arteriovenous fistula 202 (78.9)
Arteriovenous synthetic graft 7 (2.7)
Central venous catheter 
(permanent type)
47 (18.4)
Underlying renal disease
Diabetic nephropathy 80 (31.3)
Glomerulonephritis 54 (21.1)
Vascular disease 50 (19.5)
Pyelonephritis 23 (9)
Polycystic disease 16 (6.3)
Interstitial nephritis 8 (3.1)
Other 25 (9.7)
*CRP = C-reactive protein.
Figure 2. Receiver operating characteristics (ROC) curve for
C-reactive protein (CRP) as a predictor of death. Area under
curve was 0.843. Data for C-reactive protein values were
collected from 232 maintenance hemodialysis patients. The CRP
cutoff value where the sensitivity and specificity were the highest
(80% and 70%, respectively) was 6.2 mg/L.
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Follow-Up
After the three baseline CRP measurements, the
patients were followed-up at 24 months. Date and cause of
patient’s death as an outcome measure was recorded,
reviewed, and assigned an underlying cause by a panel of
three physicians. Autopsy reports were obtained in as
many cases as possible. As part of the review process, all
available medical information on each death was col-
lected, always including study and hospitalization records.
In the case of an out-of-hospital death, family members
were interviewed by telephone to ascertain the circum-
stances of death. Causes of death were classified as cardio-
vascular events (myocardial infarction, congestive heart
failure, or stroke), infection (sepsis or pneumonia), or
other causes (malignant tumors or hyperkalemia). Twenty-
four patients who received a kidney transplant during the
follow-up were excluded from the analysis.
Statistical Analysis
Data were recorded using Microsoft Excel® (Microsoft
Corporation, Redmond, WA, USA), and expressed either as
means with standard deviation (±SD) or median with
range. A Mann-Whitney U-test was used to compare the
groups. Kaplan-Meier curves were used for an analysis of
survival. The CRP cutoff value predictive of increased
mortality was determined by Receiver Operating Charac-
teristic (ROC) curve. The cutoff point for CRP, as a pre-
dictor of clinical outcome, reached 80% sensitivity and
70% specificity (see Figure 2). The area under the ROC
curve (mean±SEM) was 0.843 ± 0.028, with 95% confi-
dence interval of 0.788–0.898 and p<0.001. A p value
<0.05 was considered statistically significant. Statistical
analysis was performed with Prism® 4 (GraphPad Soft-
ware Inc., San Diego, CA, USA).
RESULTS
We analyzed a total of 232 prevalent hemodialysis
patients. CRP concentration above the cutoff point of
>6.2 mg/L was found in as many as 129 (55.6%) patients
(see Figure 1). Baseline serum concentrations of albumin
were within the normal laboratory limits or slightly below
the lower range, indicating a relatively acceptable nutri-
tional status of our patients at the beginning of the study
(see Table 1).
During the two-year follow-up, 59 patients died: 8
patients in group 1 (10%), 4 patients in group 2 (17%),
6 patients in group 3 (35%), and 41 patients in group 4
(37%). The most frequent cause of death was cardiovascular
event (see Table 2). Over two-thirds of patients who
died during the follow-up belonged to groups 3 and 4,
i.e., they had the mean baseline CRP concentration
above the cutoff point of 6.2 mg/L. In these patients,
cardiovascular events were the predominant causes of
death (see Table 2). The proportion of non-cardiovascu-
lar death events was higher in groups 1 and 2—that is,
in patients with lower mean baseline CRP value (see
Table 3).
The four groups of patients significantly differed in
survival rate (χ2=19.67; p<0.001; see Figure 3). There was
no significant difference in the survival rate between
groups 1 and 2, which both had a mean baseline CRP
value below the cutoff point of 6.2 mg/L. Nor was there a
significant difference in survival rate between the groups 3
and 4. However, a significantly higher mortality was
found in group 3 when compared with groups 1 and 2
(χ2=11.97; p<0.001). Also, group 4 had a significantly
higher mortality when compared with groups 1 and 2
(χ2=14.40; p<0.001).
Table 2 
Causes of death in 59 chronic hemodialysis patients during 
two-year follow-up
Cause of death Number of patients (%)
Cardiovascular event
Myocardial infarction 16 (27.1)
Congestive heart failure 13 (22.0)
Stroke 9 (15.3)
Infection
Sepsis 10 (16.9)
Pneumonia 4 (6.8)
Other causes
Malignant tumors 5 (8.5)
Hyperkalemia 2 (3.4)
Table 3 
Distribution of cardiovascular and non-cardiovascular 
causes of death according to the baseline serum 
concentration of C-reactive protein (CRP) in 59 chronic 
hemodialysis patients who died during two-year follow-up
CRP (mg/L)
Number of patients (%)
Cardiovascular
cause of death 
(n = 38)
Non-cardiovascular
cause of death 
(n = 21)
<3.0 (n = 8) 3 (37.5) 5 (62.5)
3.0–6.1 (n = 4) 1 (25.0) 3 (75.0)
6.2–10.0 (n = 6) 4 (66.7) 2 (33.3)
>10.0 (n = 41) 30 (73.2) 11 (26.8)
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In comparison with survivors, non-survivors had a
significantly higher median concentration of CRP (2.3 mg/
L vs. 19.0 mg/L, respectively) and wider range of CRP
values, which were up to twice the values of CRP found in
survivors (see Figure 4).
DISCUSSION
The CRP cutoff point of 6.2 mg/L was found to predict
increased mortality in these patients with ESRD. 
Considering the fact that the median CRP concentra-
tion is about 1.5 mg/L in the general population, the
majority of patients with ESRD could be considered to
have chronic inflammation.[23] Because it is common in
that population of patients, chronic inflammation has
recently become intensively investigated as a major novel
cardiovascular risk factor. However, different studies have
determined different cutoff points of CRP that were pre-
dictive of increased overall and cardiovascular mortality.
Analyzing the data from the Modification of Diet in Renal
Disease Study, Menon et al.[24] identified higher mortality
in chronic renal patients with CRP concentration above
3 mg/L. The patients with chronic renal disease but not yet
on dialysis are also at an increased mortality risk, but their
CRP concentration is lower than that in patients with
ESRD.[24] In the current study, increased mortality risk
was found only for the patients with CRP concentration
above the cutoff point of 6.2 mg/L. Owen et al.[25] also
used 3 mg/L as a cutoff point in their study and found that
more than one-third of their patients had CRP values
above that level. However, they found no significant cor-
relation with mortality. Obviously, it was not an appropri-
ate CRP cutoff point to predict increased mortality risk
(i.e., it was too low), which is in agreement with our
results. Chauveau et al.[26] used 5 mg/L as a cutoff point
and found that 69% of their patients had CRP concentra-
tion above that value. On the other hand, Tellingen
et al.[27] used 8 mg/L, and Iseki et al.[15] used 10 mg/L as
their cutoff values. In all of these studies, patients with
CRP values above the chosen cutoff point were at an
increased risk of overall and cardiovascular mortality. Dif-
ferent cutoff points obtained by different authors could be
rather confusing. The current authors’ data showed that a
possible cutoff point could be in the middle of those
reported previously (i.e., closer to the lower values). Simi-
larly to these data, Nascimento et al.[16] found a lower CRP
cutoff point to be predictive of increased mortality in
patients with ESRD.
Three consecutive measurements of CRP value were
taken in the current study because a single measurement
could not be sufficiently accurate for assessment of
inflammation, considering possible intra-individual varia-
tions. A recent Brazilian study[16] also confirmed that fluc-
tuating CRP values could lead to false interpretation of
inflammatory state, as only persistent inflammation is an
important predictor of death. Data from the study of
Tsirpanlis et al.[28] showed that average of two consecutive
CRP measurements was a reliable indicator of inflamma-
tion in about 70% of study patients. A greater number of
Figure 3. Kaplan-Meier estimates of survival of hemodialysis
patients during two-year follow-up with respect to all-cause
mortality and serum concentrations of C-reactive protein
(CRP). Significantly higher mortality was observed in patients
with CRP >6.2 mg/L. Dashed line: group 1 (CRP <3.0 mg/L);
full line: group 2 (CRP 3.0–6.1 mg/L); dotted line: group 3
(CRP 6.2–10.0 mg/L); dot-dash line: group 4 (CRP >10.0 mg/
L). p<0.001 for group 3 vs. groups 1 and 2 and for group 4 vs.
groups 1 and 2.
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Figure 4. Mean values and distribution of C-reactive protein
(CRP) in 173 survivors and 59 non-survivors at the beginning of
hemodialysis treatment. Median serum concentration of CRP in
non-survivors was significantly higher (open box) than CRP
concentration in survivors (full box): 19.0 (1.5–99.7) mg/L vs.
2.3 (0.1–49.1) mg/L, respectively. p<0.001, Mann-Whitney U
test.
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measurements (up to five) in a healthy population
improved the CRP assessment, but only slightly.[29]
The present authors found the patients with increased
CRP values to be at increased risk of cardiovascular death,
which is in accordance with results of Zimmermann et
al.[30] On the other hand, Korevaar et al.[31] found that the
mortality risk increased with an increase in the CRP level
during a single dialysis session in 25% of the patients, but
it was not associated with increased CRP values before the
dialysis session. The impact of these findings underlies the
importance of understanding which factors might cause
inflammatory response. However, the precise mechanisms
still remain unclear. A possible contribution of the hemo-
dialysis procedure per se on inflammatory response, espe-
cially choice of membrane and dialysis fluid quality, still
needs to be confirmed.
This study had several limitations. First, only CRP
was analyzed, whereas other inflammatory markers were
not assessed. Second, in the nutritional evaluation of our
patients, the Subjective Global Assessment (SGA) was not
used, as was proposed by Dialysis Outcome Quality Initia-
tive (DOQI) guidelines.[32] Only a single albumin mea-
surement at the beginning of the study was used. Third,
only the initial three consecutive CRP levels were ana-
lyzed, but not the levels at the time of the overall and car-
diovascular death event. However, CRP level at that time
of death event cannot be predictive, as the CRP levels may
vary widely depending on the cause of death.
In conclusion, the current study’s findings suggest
that CRP as a prototypical acute phase protein in humans
is a strong predictor of overall and cardiovascular mortal-
ity in patients with ESRD. A standard CRP cutoff point in
patients with ESRD should be further investigated and
confirmed in multicentric large clinical studies, including
possible interventional strategies to control the CRP val-
ues below the cutoff point.
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